Etidronic acid (BioDeep_00000003376)
Secondary id: BioDeep_00001867712
natural product human metabolite PANOMIX_OTCML-2023 blood metabolite Chemicals and Drugs
代谢物信息卡片
(1-Hydroxyethylene)diphosphonic acid, tetrapotassium salt
化学式: C2H8O7P2 (205.9745)
中文名称: 羟基乙叉二膦酸, 羟基乙叉二膦酸(HEDP)
谱图信息:
最多检出来源 Homo sapiens(blood) 61.17%
分子结构信息
SMILES: CC(O)(P(=O)(O)O)P(=O)(O)O
InChI: InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
描述信息
Etidronic acid is only found in individuals that have used or taken this drug. It is a diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]Bisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid does not interfere with bone mineralization. In malignancy-related hypercalcemia, etidronic acid decreases serum calcium by inhibiting tumour-induced bone resorption and reducing calcium flow from the resorbing bone into the blood. Etidronic acid also reduces morbidity of osteolytic bone metastases by inhibiting tumour-induced bone resorption. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.
Food contaminant arising from its use as a boiler water additive for prepn. of steam used in food processing. Component of antimicrobial washes for poultry carcasses and fruit
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
KEIO_ID E010
同义名列表
74 个代谢物同义名
(1-Hydroxyethylene)diphosphonic acid, tetrapotassium salt; Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt; (1-hydroxy-1-phosphonoethyl)phosphonic acid; 1-Hydroxyethylidene-1,1-bisphosphonic acid; 1-Hydroxyethylene diphosphonate, disodium; 1-Hydroxyethylidene-1,1-diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonic acid); Diphosphonate, disodium 1-hydroxyethylene; Disodium 1-hydroxyethylene diphosphonate; Disodium 1 hydroxyethylene diphosphonate; (1-Hydroxyethylidene)bisphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonic acid; (1-Hydroxyethylidene)diphosphonic acid; 1-Hydroxyethane-1,1-bisphosphonic acid; 1 Hydroxyethylidene 1,1 bisphosphonate; Ethane-1-hydroxy-1,1-diphosphonic acid; 1-Hydroxyethylidene-1,1-bisphosphonate; 1-Hydroxyethylidene-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonic acid; (1-Hydroxyethylidene)bis(phosphonate); (Hydroxyethylidene)diphosphonic acid; Diphosphonic acid, hydroxyethylidene; (1-Hydroxyethylene)diphosphonic acid; 1,1,1-Ethanetriol diphosphonic acid; Hydroxyethylidene diphosphonic acid; Ethane-1-hydroxy-1,1-bisphosphonate; (1-Hydroxyethylidene)bisphosphonate; (1-Hydroxyethylidene)diphosphonate; 1-Hydroxyethane-1,1-bisphosphonate; Ethane-1-hydroxy-1,1-diphosphonate; 1-Hydroxyethane-1,1-diphosphonate; 1 Hydroxyethane 1,1 diphosphonate; 1,1-Hydroxyethylenediphosphonate; 1-Hydroxyethanediphosphonic acid; 1,1 Hydroxyethylenediphosphonate; (Hydroxyethylidene)diphosphonate; (1-Hydroxyethylene)diphosphonate; 1-Hydroxy-1,1-diphosphonoethane; Salt etidronate, tetrapotassium; 1,1,1-Ethanetriol diphosphonate; Etidronate, tetrapotassium salt; Oxyethylidenediphosphonic acid; Tetrapotassium salt etidronate; Hydroxyethanediphosphonic acid; 1-Hydroxyethanediphosphonate; Oxyethylidenediphosphonate; Ethanehydroxydiphosphonate; Hydroxyethanediphosphonate; Ethanehydroxyphosphate; Acetodiphosphonic acid; Etidronate, dicalcium; Dicalcium etidronate; Etidronate, disodium; Etidronate disodium; Disodium etidronate; Acetodiphosphonate; Acidum etidronicum; Etidronate, sodium; Sodium etidronate; Acide etidronique; Acido etidronico; EHDP, dicalcium; Etidronic acid; Dicalcium ehdp; Etidronsaeure; Etidronate; Xydiphone; Didronel; Xidiphon; Xidifon; HEDSPA; HEDP; EHDP; Etidronic acid
数据库引用编号
28 个数据库交叉引用编号
- ChEBI: CHEBI:4907
- KEGG: C07736
- KEGGdrug: D02373
- PubChem: 3305
- HMDB: HMDB0015210
- Metlin: METLIN2629
- DrugBank: DB01077
- ChEMBL: CHEMBL871
- Wikipedia: Etidronic_acid
- MeSH: Etidronic Acid
- foodb: FDB001018
- chemspider: 3189
- CAS: 2809-21-4
- MoNA: KO000712
- MoNA: PS022801
- MoNA: KO000711
- MoNA: KO000713
- MoNA: PS022807
- MoNA: PS022803
- MoNA: KO000709
- MoNA: KO000710
- MoNA: PS022802
- PMhub: MS000009565
- PubChem: 9938
- PDB-CCD: 911
- NIKKAJI: J7.915D
- RefMet: Etidronic acid
- KNApSAcK: 4907
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sawita Suwannarat, Naowarat Tephiruk, Suwanna Sunan, Khomsan Ruangwong, Siwapon Srisonphan. Disinfection Efficacy of Electrohydraulic Discharge Plasma against Xanthomonas campestris pv campestris: A Sustainable Seed Treatment Approach.
ACS applied bio materials.
2024 Mar; 7(3):1469-1477. doi:
10.1021/acsabm.3c00862. [PMID: 38231151] - Fatemeh Gholamian, Naser Karimi, Forouzan Gholamian, Parviz Bayat. Phycoremediation potential and agar yield of red macroalgae (Gracilaria corticata) against HEDP (hydroxyethylidene diphosphonic acid) and CAPB (cocoamidopropyl betaine) detergents and the heavy metal pollutants.
Environmental science and pollution research international.
2023 Aug; ?(?):. doi:
10.1007/s11356-023-29427-3. [PMID: 37648916] - Nancy Waltman, Kevin A Kupzyk, Laura E Flores, Lynn R Mack, Joan M Lappe, Laura D Bilek. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2022 Feb; 33(2):475-486. doi:
10.1007/s00198-021-06083-2. [PMID: 34519832] - Koichi Ishida, Naoki Ashizawa, Shota Morikane, Naoki Kurita, Seiichi Kobashi, Takashi Iwanaga. Assessment of calciprotein particle formation by AUC of the absorbance change: effect of FYB-931, a novel bisphosphonate compound.
The Journal of pharmacy and pharmacology.
2021 Jun; 73(7):947-955. doi:
10.1093/jpp/rgab019. [PMID: 33882129] - Naohito Yambe, Riyoko Tamai, Izumi Mashima, Yusuke Kiyoura. Etidronate down-regulates Toll-like receptor 2 ligand-induced chemokine production by inhibiting MyD88 expression and NF-κB activation.
Immunopharmacology and immunotoxicology.
2021 Feb; 43(1):51-57. doi:
10.1080/08923973.2020.1850761. [PMID: 33251898] - Koichi Ishida, Naoki Ashizawa, Koji Matsumoto, Seiichi Kobashi, Naoki Kurita, Takashi Shigematsu, Takashi Iwanaga. Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats.
Journal of bone and mineral metabolism.
2019 Sep; 37(5):796-804. doi:
10.1007/s00774-019-00987-0. [PMID: 30712064] - Shawn Patrick Zinnen, Alexander Karpeisky, Daniel D Von Hoff, Larisa Plekhova, Alexander Alexandrov. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.
The oncologist.
2019 03; 24(3):303-e102. doi:
10.1634/theoncologist.2018-0707. [PMID: 30413669] - Carolin Bauer, Olivier le Saux, Viola Pomozi, Redouane Aherrahrou, Rene Kriesen, Stephanie Stölting, Annett Liebers, Thorsten Kessler, Heribert Schunkert, Jeanette Erdmann, Zouhair Aherrahrou. Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation.
Scientific reports.
2018 04; 8(1):5812. doi:
10.1038/s41598-018-24228-y. [PMID: 29643466] - Kentaro Hojo, Riyoko Tamai, Michiyo Kobayashi-Sakamoto, Yusuke Kiyoura. Etidronate down-regulates Toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-κB activation.
Pharmacological reports : PR.
2017 Aug; 69(4):773-778. doi:
10.1016/j.pharep.2017.03.009. [PMID: 28587938] - Viola Pomozi, Christopher Brampton, Koen van de Wetering, Janna Zoll, Bianca Calio, Kevin Pham, Jesse B Owens, Joel Marh, Stefan Moisyadi, András Váradi, Ludovic Martin, Carolin Bauer, Jeanette Erdmann, Zouhair Aherrahrou, Olivier Le Saux. Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice.
The American journal of pathology.
2017 Jun; 187(6):1258-1272. doi:
10.1016/j.ajpath.2017.02.009. [PMID: 28416300] - Qiaoli Li, Joshua Kingman, John P Sundberg, Michael A Levine, Jouni Uitto. Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy.
The Journal of investigative dermatology.
2016 Jan; 136(1):275-283. doi:
10.1038/jid.2015.377. [PMID: 26763447] - V Fadda, D Maratea, S Trippoli, A Messori. Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Journal of endocrinological investigation.
2015 Feb; 38(2):189-92. doi:
10.1007/s40618-014-0211-5. [PMID: 25412945] - Aydan Oral, Roman Lorenc. Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Acta orthopaedica et traumatologica turcica.
2015; 49(1):67-74. doi:
10.3944/aott.2015.14.0082. [PMID: 25803256] - Young Hwan Seo, Yoon Hee Chung, Cheol-Hee Lim, Ji Hoon Jeong. UPLC-UV method for determination of risedronate in human urine.
Journal of chromatographic science.
2014 Aug; 52(7):713-8. doi:
10.1093/chromsci/bmt105. [PMID: 23851998] - Swetha Rathan, Ajit P Yoganathan, Charles W O'Neill. The role of inorganic pyrophosphate in aortic valve calcification.
The Journal of heart valve disease.
2014 Jul; 23(4):387-94. doi:
. [PMID: 25803964] - J P Brown, C Roux, P R Ho, M A Bolognese, J Hall, H G Bone, S Bonnick, J P van den Bergh, I Ferreira, P Dakin, R B Wagman, C Recknor. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2014 Jul; 25(7):1953-61. doi:
10.1007/s00198-014-2692-7. [PMID: 24676847] - Yuji Kasukawa, Naohisa Miyakoshi, Toshihito Ebina, Toshiaki Aizawa, Michio Hongo, Koji Nozaka, Yoshinori Ishikawa, Hidetomo Saito, Shuichi Chida, Yoichi Shimada. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Journal of bone and mineral metabolism.
2014 May; 32(3):290-7. doi:
10.1007/s00774-013-0490-5. [PMID: 23846118] - Shiro Tanaka, Teruhiko Miyazaki, Yukari Uemura, Tatsuhiko Kuroda, Nobuaki Miyakawa, Toshitaka Nakamura, Masao Fukunaga, Yasuo Ohashi, Hiroaki Ohta, Satoshi Mori, Hiroshi Hagino, Takayuki Hosoi, Toshitsugu Sugimoto, Eiji Itoi, Hajime Orimo, Masataka Shiraki. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Journal of bone and mineral metabolism.
2014 May; 32(3):298-304. doi:
10.1007/s00774-013-0491-4. [PMID: 23828145] - Mark F McCarty, James J DiNicolantonio. The molecular biology and pathophysiology of vascular calcification.
Postgraduate medicine.
2014 Mar; 126(2):54-64. doi:
10.3810/pgm.2014.03.2740. [PMID: 24685968] - R Simanjuntak, E Setiawati, D A Yunaidi, L R Handayani, A Setiawati, B S Utami, T A Rosa, A B Sholeh. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
Drug research.
2014 Mar; 64(3):136-40. doi:
10.1055/s-0033-1354365. [PMID: 24002927] - Yohann Bala, Roland Chapurlat, Angela M Cheung, Dieter Felsenberg, Michel LaRoche, Edward Morris, Jonathan Reeve, Thierry Thomas, Jose Zanchetta, Oliver Bock, Ali Ghasem-Zadeh, Roger Martin Zebaze Djoumessi, Ego Seeman, René Rizzoli. Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2014 Feb; 29(2):380-8. doi:
10.1002/jbmr.2101. [PMID: 24115129] - David Banji, Otilia J F Banji, Vijaya Laxmi Chiluka, Saidulu Abbagoni. Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
Indian journal of experimental biology.
2014 Feb; 52(2):153-8. doi:
NULL. [PMID: 24597148] - Il-Woo Jung, Hyo-Kyung Han. Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization.
International journal of nanomedicine.
2014; 9(?):2299-306. doi:
10.2147/ijn.s61181. [PMID: 24872692] - Naglaa F Khedr, Nahla E El-Ashmawy, Hoda A El-Bahrawy, Ali A Haggag, Eman E El-Abd. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Fundamental & clinical pharmacology.
2013 Oct; 27(5):526-34. doi:
10.1111/j.1472-8206.2012.01047.x. [PMID: 22762129] - Chris Or, Jing Cui, Joanne Matsubara, Farzin Forooghian. Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells.
The British journal of ophthalmology.
2013 Aug; 97(8):1074-8. doi:
10.1136/bjophthalmol-2013-303355. [PMID: 23766431] - Ali Ozdemir, Aysegül Dalbeler, Aslı Bilen, Can Sevinc, Elvan Isık. Acute renal failure associated with diphosphonic acid (HEDP): a case report.
American journal of industrial medicine.
2013 Jun; 56(6):720-3. doi:
10.1002/ajim.22189. [PMID: 23533056] - Jean-Pierre Devogelaer, Philip Sambrook, David M Reid, Stefan Goemaere, Sophia Ish-Shalom, Julien Collette, Guoqin Su, Christina Bucci-Rechtweg, Philemon Papanastasiou, Jean-Yves Reginster. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Rheumatology (Oxford, England).
2013 Jun; 52(6):1058-69. doi:
10.1093/rheumatology/kes410. [PMID: 23365149] - Richard Choo, Himu Lukka, Patrick Cheung, Tom Corbett, Rosario Briones-Urbina, Reinhold Vieth, Lisa Ehrlich, Alex Kiss, Cyril Danjoux. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
International journal of radiation oncology, biology, physics.
2013 Apr; 85(5):1239-45. doi:
10.1016/j.ijrobp.2012.11.007. [PMID: 23265571] - Jesse E Otero, Gary S Gottesman, William H McAlister, Steven Mumm, Katherine L Madson, Tina Kiffer-Moreira, Campbell Sheen, José Luis Millán, Karen L Ericson, Michael P Whyte. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2013 Feb; 28(2):419-30. doi:
10.1002/jbmr.1752. [PMID: 22972716] - Yoshihiro Nishida, Yoshihisa Yamada, Satoshi Tsukushi, Hideshi Sugiura, Hiroshi Urakawa, Naoki Ishiguro. Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan.
Clinical rheumatology.
2013 Feb; 32(2):241-5. doi:
10.1007/s10067-012-2109-y. [PMID: 23138882] - Ho Yeon Chung, Jawon Koo, Su Kyoung Kwon, Moo-Il Kang, Seong-Hwan Moon, Jin-Young Park, Chan Soo Shin, Byung-Koo Yoon, Hyun-Koo Yoon, Jae-Suk Chang, Yoon-Sok Chung, Hyoung-Moo Park. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Clinical interventions in aging.
2013; 8(?):597-603. doi:
10.2147/cia.s44395. [PMID: 23761968] - J S Thomsen, T S Straarup, C C Danielsen, H Oxlund, A Brüel. No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
Scandinavian journal of rheumatology.
2013; 42(5):408-16. doi:
10.3109/03009742.2013.774046. [PMID: 23527881] - Pilar Peris, Elizabeth J Atkinson, Mario Gössl, Trevor L Kane, Louise K McCready, Amir Lerman, Sundeep Khosla, Ulrike I McGregor. Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Mayo Clinic proceedings.
2013 Jan; 88(1):46-55. doi:
10.1016/j.mayocp.2012.08.019. [PMID: 23228561] - Valeria Cohran, Amy Cassedy, Andre Hawkins, Judy Bean, James Heubi. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
Journal of pediatric rehabilitation medicine.
2013; 6(2):85-93. doi:
10.3233/prm-130242. [PMID: 23803341] - Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Drug metabolism and disposition: the biological fate of chemicals.
2012 Dec; 40(12):2332-41. doi:
10.1124/dmd.112.047068. [PMID: 22961681] - Sung Jin Bae, Beom-Jun Kim, Kyeong Hye Lim, Seung Hun Lee, Hong Kyu Kim, Ghi Su Kim, Jung-Min Koh. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Journal of bone and mineral metabolism.
2012 Sep; 30(5):588-95. doi:
10.1007/s00774-012-0361-5. [PMID: 22610063] - Catherine Van Poznak, Andreas Makris, Glen Clack, David H Barlow, Richard Eastell. Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Breast cancer research and treatment.
2012 Aug; 134(3):1141-7. doi:
10.1007/s10549-012-2147-9. [PMID: 22763465] - Maria Coco, James Pullman, Hillel W Cohen, Sally Lee, Craig Shapiro, Clemencia Solorzano, Stuart Greenstein, Daniel Glicklich. Effect of risedronate on bone in renal transplant recipients.
Journal of the American Society of Nephrology : JASN.
2012 Aug; 23(8):1426-37. doi:
10.1681/asn.2011060623. [PMID: 22797188] - M L Frost, M Siddique, G M Blake, A E Moore, P K Marsden, P J Schleyer, R Eastell, I Fogelman. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2012 Aug; 23(8):2107-16. doi:
10.1007/s00198-011-1805-9. [PMID: 21983795] - E A Yur'eva, V S Sukhorukov, A N Murashov, M S Pimenov, I A Ilyushina, A A Dreval. Biochemical indicators of atherogenic and protective activity of xydiphone in experimental animals.
Bulletin of experimental biology and medicine.
2012 Aug; 153(4):459-62. doi:
10.1007/s10517-012-1740-6. [PMID: 22977844] - Hiroko Mori, Yosuke Okada, Yoshiya Tanaka, Osamu Hashimoto. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
Clinical calcium.
2012 Jul; 22(7):1034-42. doi:
clica120710341042. [PMID: 22750936] - José V Torregrosa, Carlos E Durán, Xoana Barros, Miquel Blasco, Marta Arias, Aleix Cases, Josep M Campistol. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.
2012 May; 32(3):329-34. doi:
10.3265/nefrologia.pre2012.jan.11137. [PMID: 22592420] - Murat Zinnuroglu, Aylin Sepici Dincel, Funda Kosova, Vesile Sepici, Gulcin Kaymak Karatas. Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
Rheumatology international.
2012 Apr; 32(4):875-80. doi:
10.1007/s00296-010-1708-7. [PMID: 21221594] - Yu Chen, Yuxiu Liu, Zhidong Chen, Meilan Chen, Yan Zhu. [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Se pu = Chinese journal of chromatography.
2012 Apr; 30(4):414-8. doi:
10.3724/sp.j.1123.2011.12070. [PMID: 22799202] - C Roux, D M Reid, J-P Devogelaer, K Saag, C S Lau, J-Y Reginster, P Papanastasiou, C Bucci-Rechtweg, G Su, P N Sambrook. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2012 Mar; 23(3):1083-90. doi:
10.1007/s00198-011-1800-1. [PMID: 21975559] - S A Polyzos, A D Anastasilakis, C Bratengeier, W Woloszczuk, A Papatheodorou, E Terpos. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2012 Mar; 23(3):1171-6. doi:
10.1007/s00198-010-1525-6. [PMID: 21305266] - Sussan Ghassabian, Linda A Wright, Andrew D Dejager, Maree T Smith. Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Jan; 881-882(?):34-41. doi:
10.1016/j.jchromb.2011.11.031. [PMID: 22197608] - Natalya A Muraleva, Evgeniy N Ofitserov, Vladimir P Tikhonov, Natalya G Kolosova. Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model.
The Indian journal of medical research.
2012; 135(?):221-7. doi:
NULL. [PMID: 22446865] - L A Bradbury, S Barlow, F Geoghegan, R A Hannon, S L Stuckey, J A H Wass, R G G Russell, M A Brown, E L Duncan. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2012 Jan; 23(1):285-94. doi:
10.1007/s00198-011-1658-2. [PMID: 21739105] - Masayuki Takakuwa, Jun Iwamoto. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Biological & pharmaceutical bulletin.
2012; 35(7):1159-65. doi:
10.1248/bpb.b12-00200. [PMID: 22791166] - Jelena S Rudic, Vanja Giljaca, Miodrag N Krstic, Goran Bjelakovic, Christian Gluud. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
The Cochrane database of systematic reviews.
2011 Dec; ?(12):CD009144. doi:
10.1002/14651858.cd009144.pub2. [PMID: 22161446] - Funda Kont Cobankara, Hilal Erdogan, Mehmet Hamurcu. Effects of chelating agents on the mineral content of root canal dentin.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
2011 Dec; 112(6):e149-54. doi:
10.1016/j.tripleo.2011.06.037. [PMID: 22014997] - K Amagase, A Inaba, T Senta, Y Ishikawa, K Nukui, T Murakami, Koji Takeuchi. Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
2011 Dec; 62(6):609-18. doi:
. [PMID: 22314563] - P Peris, M Torra, V Olivares, R Reyes, A Monegal, A Martínez-Ferrer, N Guañabens. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Bone.
2011 Oct; 49(4):706-9. doi:
10.1016/j.bone.2011.06.027. [PMID: 21742070] - Sydney Lou Bonnick. Going on a drug holiday?.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
2011 Oct; 14(4):377-83. doi:
10.1016/j.jocd.2011.07.006. [PMID: 22051091] - P S M Lai, S S Chua, Y Y Chew, S P Chan. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Journal of clinical pharmacy and therapeutics.
2011 Oct; 36(5):557-67. doi:
10.1111/j.1365-2710.2010.01210.x. [PMID: 21916908] - K Izumi, A Mizokami, K Sugimoto, K Narimoto, Y Kitagawa, E Koh, M Namiki. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
Prostate cancer and prostatic diseases.
2011 Sep; 14(3):238-42. doi:
10.1038/pcan.2011.10. [PMID: 21423267] - Glen M Blake, Michelle L Frost, Amelia E B Moore, Musib Siddique, Ignac Fogelman. The assessment of regional skeletal metabolism: studies of osteoporosis treatments using quantitative radionuclide imaging.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
2011 Jul; 14(3):263-71. doi:
10.1016/j.jocd.2011.04.003. [PMID: 21600822] - Sonsoles Guadalix, Guillermo Martínez-Díaz-Guerra, David Lora, Carmela Vargas, Miren Gómez-Juaristi, Belén Cobaleda, Enrique Moreno González, Federico Hawkins. Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Transplant international : official journal of the European Society for Organ Transplantation.
2011 Jul; 24(7):657-65. doi:
10.1111/j.1432-2277.2011.01253.x. [PMID: 21466595] - Ho-Yeon Chung, Sang Ouk Chin, Moo-I L Kang, Jung-Min Koh, Sung-Hwan Moon, Byung-Koo Yoon, Hyun-Koo Yoon, Yoon-Sok Chung, Hyoung-Moo Park. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Clinical endocrinology.
2011 Jun; 74(6):699-704. doi:
10.1111/j.1365-2265.2011.04041.x. [PMID: 21521310] - Carolyn J Crandall, Chi-Hong Tseng, Sybil L Crawford, Rebecca C Thurston, Ellen B Gold, Janet M Johnston, Gail A Greendale. Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
2011 Apr; 26(4):840-9. doi:
10.1002/jbmr.259. [PMID: 20878774] - Susana Morelli, Paola Scodelaro Bilbao, Sebastian Katz, Virginia Lezcano, Emilio Roldán, Ricardo Boland, Graciela Santillan. Protein phosphatases: possible bisphosphonate binding sites mediating stimulation of osteoblast proliferation.
Archives of biochemistry and biophysics.
2011 Mar; 507(2):248-53. doi:
10.1016/j.abb.2010.12.013. [PMID: 21167123] - F Furukawa, C Kaminaka, T Ikeda, N Kanazawa, Y Yamamoto, C Ohta, T Nishide, K Tsujioka, M Hattori, K Uede, M Hata. Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy.
Clinical and experimental dermatology.
2011 Mar; 36(2):165-8. doi:
10.1111/j.1365-2230.2010.03856.x. [PMID: 20497186] - Cai-Mei Zheng, Kuo-Cheng Lu, Chia-Chao Wu, Yung-Ho Hsu, Yuh-Feng Lin. Association of Serum Phosphate and Related Factors in ESRD-Related Vascular Calcification.
International journal of nephrology.
2011; 2011(?):939613. doi:
10.4061/2011/939613. [PMID: 21660259] - Laëtitia Michou, Jacques P Brown. Emerging strategies and therapies for treatment of Paget's disease of bone.
Drug design, development and therapy.
2011; 5(?):225-39. doi:
10.2147/dddt.s11306. [PMID: 21607019] - Keiji Okamoto, Masaaki Inaba, Yutaka Furumitsu, Akihiko Ban, Naoto Mori, Kazuhiko Yukioka, Yasuo Imanishi, Yoshiki Nishizawa. Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.
Life sciences.
2010 Dec; 87(23-26):686-91. doi:
10.1016/j.lfs.2010.10.006. [PMID: 20951147] - I Kh Valeeva, A F Titarenko, L E Ziganshina. [Comparative analysis of dimephosphon, ionol, and xydiphone effects on indomethacin-induced gastric lesions in rats].
Eksperimental'naia i klinicheskaia farmakologiia.
2010 Dec; 73(12):21-4. doi:
NULL. [PMID: 21395012] - Zhaoping Li, Hannah Karp, Alona Zerlin, Tsz Ying Amy Lee, Catherine Carpenter, David Heber. Absorption of silicon from artesian aquifer water and its impact on bone health in postmenopausal women: a 12 week pilot study.
Nutrition journal.
2010 Oct; 9(?):44. doi:
10.1186/1475-2891-9-44. [PMID: 20946656] - Masataka Shiraki, Yasushi Yamazaki, Yumiko Shiraki, Takayuki Hosoi, Naoko Tsugawa, Toshio Okano. High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Journal of bone and mineral metabolism.
2010 Sep; 28(5):578-84. doi:
10.1007/s00774-010-0167-2. [PMID: 20221651] - N L Waltman, J J Twiss, C D Ott, G J Gross, A M Lindsey, T E Moore, K Berg, K Kupzyk. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
2010 Aug; 21(8):1361-9. doi:
10.1007/s00198-009-1083-y. [PMID: 19802506] - Michael Pazianas, Cyrus Cooper, F Hal Ebetino, R Graham G Russell. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
Therapeutics and clinical risk management.
2010 Jul; 6(?):325-43. doi:
10.2147/tcrm.s8054. [PMID: 20668715] - Kousei Yoh, Shinjiro Takata, Noriko Yoshimura, Jun Hashimoto. Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.
Journal of bone and mineral metabolism.
2010 Jul; 28(4):468-76. doi:
10.1007/s00774-009-0152-9. [PMID: 20179977] - José-Vicente Torregrosa, David Fuster, Miguel-Angel Gentil, Roberto Marcen, Luís Guirado, Sofía Zarraga, Juan Bravo, Dolores Burgos, Ana Monegal, Africa Muxí, Sagrario García. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.
Transplantation.
2010 Jun; 89(12):1476-81. doi:
10.1097/tp.0b013e3181dc13d0. [PMID: 20393402] - Jan Martel, Cheng-Yeu Wu, John D Young. Critical evaluation of gamma-irradiated serum used as feeder in the culture and demonstration of putative nanobacteria and calcifying nanoparticles.
PloS one.
2010 Apr; 5(4):e10343. doi:
10.1371/journal.pone.0010343. [PMID: 20436679] - Mojca Jensterle, Marija Pfeifer, Matjaz Sever, Tomaz Kocjan. Dihydrotachysterol intoxication treated with pamidronate: a case report.
Cases journal.
2010 Mar; 3(?):78. doi:
10.1186/1757-1626-3-78. [PMID: 20507648] - Damir Obad, Niels A Larsen, Erling B Pedersen. [Regression of severe periarticular calcifications during treatment with bisphosphonate in a dialysis patient].
Ugeskrift for laeger.
2010 Mar; 172(9):719-21. doi:
NULL. [PMID: 20199755] - Kurt M Sowers, Melvin R Hayden. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches.
Oxidative medicine and cellular longevity.
2010 Mar; 3(2):109-21. doi:
10.4161/oxim.3.2.11354. [PMID: 20716935] - Seiji Ohtori, Tsutomu Akazawa, Yasuaki Murata, Tomoaki Kinoshita, Masaomi Yamashita, Koichi Nakagawa, Gen Inoue, Junichi Nakamura, Sumihisa Orita, Nobuyasu Ochiai, Shunji Kishida, Masashi Takaso, Yawara Eguchi, Kazuyo Yamauchi, Munetaka Suzuki, Yasuchika Aoki, Kazuhisa Takahashi. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2010 Feb; 17(2):209-13. doi:
10.1016/j.jocn.2009.06.013. [PMID: 20044258] - Ilaria Roato, Davide Caldo, Laura Godio, Lucia D'Amico, Paolo Giannoni, Emanuela Morello, Rodolfo Quarto, Luigi Molfetta, Paolo Buracco, Antonio Mussa, Riccardo Ferracini. Bone invading NSCLC cells produce IL-7: mice model and human histologic data.
BMC cancer.
2010 Jan; 10(?):12. doi:
10.1186/1471-2407-10-12. [PMID: 20067635] - Rolf Jorde, Monica Sneve, Peter A Torjesen, Yngve Figenschau, John-Bjarne Hansen, Guri Grimnes. No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.
Nutrition journal.
2010 Jan; 9(?):1. doi:
10.1186/1475-2891-9-1. [PMID: 20056003] - Joana Caetano-Lopes, Ana M Nery, Helena Canhão, Joana Duarte, Rita Cascão, Ana Rodrigues, Inês P Perpétuo, Saba Abdulghani, Pedro M Amaral, Shimon Sakaguchi, Yrjö T Konttinen, Luís Graça, Maria F Vaz, João E Fonseca. Chronic arthritis leads to disturbances in the bone collagen network.
Arthritis research & therapy.
2010; 12(1):R9. doi:
10.1186/ar2908. [PMID: 20078856] - Jeffrey S Willey, Eric W Livingston, Michael E Robbins, J Daniel Bourland, Leidamarie Tirado-Lee, Hope Smith-Sielicki, Ted A Bateman. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.
Bone.
2010 Jan; 46(1):101-11. doi:
10.1016/j.bone.2009.09.002. [PMID: 19747571] - Takashi Takei, Mitsuyo Itabashi, Misao Tsukada, Hidekazu Sugiura, Takahito Moriyama, Chiari Kojima, Shunji Shiohira, Ari Shimizu, Kazunori Karasawa, Nobuyuki Amemiya, Kunio Kawanishi, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Internal medicine (Tokyo, Japan).
2010; 49(19):2065-70. doi:
10.2169/internalmedicine.49.3707. [PMID: 20930431] - Takayoshi Hozuki, Tomihiro Imai, Emiko Tsuda, Akihiro Matsumura, Daisuke Yamamoto, Takanobu Toyoshima, Syuuichiro Suzuki, Rika Yamauchi, Takashi Hayashi, Shin Hisahara, Shun Shimohama. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Internal medicine (Tokyo, Japan).
2010; 49(5):371-6. doi:
10.2169/internalmedicine.49.2551. [PMID: 20190467] - Yong-Dae Kwon, Deog-Yoon Kim, Joo-Young Ohe, Ji-Yeon Yoo, Christian Walter. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
2009 Dec; 67(12):2644-8. doi:
10.1016/j.joms.2009.04.067. [PMID: 19925985] - Cheng-Yeu Wu, Jan Martel, David Young, John D Young. Fetuin-A/albumin-mineral complexes resembling serum calcium granules and putative nanobacteria: demonstration of a dual inhibition-seeding concept.
PloS one.
2009 Nov; 4(11):e8058. doi:
10.1371/journal.pone.0008058. [PMID: 19956594] - M Takakuwa, K Otsuka, M Konishi, K Itabashi. Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.
The Journal of international medical research.
2009 Nov; 37(6):1972-81. doi:
10.1177/147323000903700635. [PMID: 20146897] - Matthew M Grinsell, Victoria F Norwood. At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension.
Pediatric nephrology (Berlin, Germany).
2009 Nov; 24(11):2137-46. doi:
10.1007/s00467-008-0744-y. [PMID: 18320238] - C M Weaver, B R Martin, G S Jackson, G P McCabe, J R Nolan, L D McCabe, S Barnes, S Reinwald, M E Boris, M Peacock. Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
The Journal of clinical endocrinology and metabolism.
2009 Oct; 94(10):3798-805. doi:
10.1210/jc.2009-0332. [PMID: 19584189] - Pauli V Luoma. Gene-activators prevent and regress atherosclerosis and reduce mortality.
Cardiovascular & hematological agents in medicinal chemistry.
2009 Oct; 7(4):295-304. doi:
10.2174/187152509789541918. [PMID: 19607643] - Simon Hohenester, Ronald P J Oude-Elferink, Ulrich Beuers. Primary biliary cirrhosis.
Seminars in immunopathology.
2009 Sep; 31(3):283-307. doi:
10.1007/s00281-009-0164-5. [PMID: 19603170] - Yang Ye, Shen-Jiang Hu. Re 'Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors' by A. Luckish et al.
Bone.
2009 Sep; 45(3):609-10; author reply 611. doi:
10.1016/j.bone.2009.05.011. [PMID: 19465167] - Marnix G E H Lam, Tjitske B Bosma, Peter P van Rijk, Bernard A Zonnenberg. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
European journal of nuclear medicine and molecular imaging.
2009 Sep; 36(9):1425-33. doi:
10.1007/s00259-009-1119-8. [PMID: 19319526] - Afef Bahlous, Kahena Bouzid, Héla Sahli, Slaheddine Sallami, Jaouidia Abdelmoula. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
La Tunisie medicale.
2009 Aug; 87(8):525-6. doi:
NULL. [PMID: 20180356] - Ayako Shiraishi, Sayaka Miyabe, Takayoshi Nakano, Yukichi Umakoshi, Masako Ito, Masahiko Mihara. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
BMC musculoskeletal disorders.
2009 Jun; 10(?):66. doi:
10.1186/1471-2474-10-66. [PMID: 19527501] - Afef Bahlous, Kahena Bouzid, Héla Sahli, Slaheddine Sallami, Jaouda Abdelmoula. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
La Tunisie medicale.
2009 Jun; 87(6):380-1. doi:
NULL. [PMID: 19927782] - Kouji Izumi, Atsushi Mizokami, Kazuhiro Sugimoto, Kazutaka Narimoto, Sotaro Miwa, Yuji Maeda, Yoshifumi Kadono, Mitsuhiro Takashima, Eitetsu Koh, Mikio Namiki. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Urology.
2009 Jun; 73(6):1342-6. doi:
10.1016/j.urology.2009.01.046. [PMID: 19371939] - Jun Iwamoto, Mitsuyoshi Uzawa, Yoshihiro Sato, Tsuyoshi Takeda, Hideo Matsumoto. Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis.
Therapeutics and clinical risk management.
2009 Jun; 5(3):499-505. doi:
10.2147/tcrm.s5982. [PMID: 19707260] - Vit Zikan, Jan J Stepan. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Bone.
2009 Apr; 44(4):634-8. doi:
10.1016/j.bone.2008.12.013. [PMID: 19150421]
